Fractyl Health Inc (GUTS) Stock Price, Quote & News

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term r...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 902 8800

Website: fractyl.com

Address:

3 Van de Graaff Drive, Suite 200, Burlington, United States

LUVDAFOOD Dec. 23 at 4:26 PM

$GUTS Between 47 - 64 % discontinue GLP therapy ( nausea diarrhea) ReVita retains the gains made by GLP users - especially as to diabetes and weight profile

1 · Reply

willyield Dec. 23 at 3:15 PM

$GUTS

0 · Reply

Zkoko_Bio Dec. 23 at 1:13 AM

$GUTS $NVO Wegovy is a game changer hitting the market very soon. It also helps in keeping weight off, and that is Fractyl's territory...

0 · Reply

willyield Dec. 22 at 12:10 PM

$GUTS

0 · Reply

Ked1977 Dec. 19 at 4:19 PM

$GUTS does anyone think the Eli Lilly Orforglipron pill would be more of a competitor?

2 · Reply

SomsiHart Dec. 19 at 1:02 PM

Here are some small-cap stocks with potential to double: $ALT $MAAS $VOR $GUTS

1 · Reply

Quantumup Dec. 19 at 12:09 PM

Canaccord Genuity reiterated $GUTS Buy-$8 and said, over the last week, we hosted a number of virtual investor meetings with GUTS' Dr. Harith Rajagopalan, M.D., Ph.D (Co-founder and CEO) and Brian Luque (Head of IR and Corp Dev). Discussion spanned a range of topics including 1) the underlying mechanism of duodenal ablation, 2) Revita procedure and its clinical profile, 3) current development and regulatory status, 4) commercial opportunity and reimbursement, and 5) upcoming 6mo REMAIN-1 midpoint data readout in Jan. We came away from the discussions encouraged as it largely revolved around the commercial opportunity given the positive clinical data shared thus far. Reiterate BUY.

0 · Reply

DSAdsdsas Dec. 19 at 5:00 AM

$GUTS

0 · Reply

ppl_first Dec. 18 at 10:05 PM

$GUTS Binary: Pivotal trial readout expected H2 2026. Still the main future binary. No reported changes to that timeline or calendar in recent major news. Material recent activity: Continued development updates; cash runway extended but no specific new filings or decisions. Status: Tier 1 binary candidate for H2 2026 pivotal readout. No change in catalyst expectation.

0 · Reply

ShadowBanningIsBad Dec. 18 at 9:46 PM

$GUTS ok I may have been too early to judge DMR. Does anyone know if $GUTS has IP that gives them a moat for DMR procedures?

0 · Reply

Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones

Dec 2, 2025, 7:00 AM EST - 22 days ago

Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure

Dec 1, 2025, 7:00 AM EST - 23 days ago

Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 8:21 PM EST - 6 weeks ago

Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:05 PM EST - 6 weeks ago

Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027

Nov 5, 2025, 7:00 AM EST - 7 weeks ago

Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

Oct 7, 2025, 7:00 AM EDT - 2 months ago

Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity

Oct 1, 2025, 5:14 AM EDT - 3 months ago

Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang

Sep 26, 2025, 11:07 AM EDT - 3 months ago

Fractyl Health, Inc. - Special Call

Sep 26, 2025, 7:41 AM EDT - 3 months ago

Fractyl Health says experimental procedure helps maintain weight-loss in study

Sep 26, 2025, 7:05 AM EDT - 3 months ago

Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock

Sep 26, 2025, 7:00 AM EDT - 3 months ago

Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation

Sep 5, 2025, 6:05 PM EDT - 3 months ago

Fractyl Health: One-Time Procedure To Lock-In GLP-1 Weight Loss; High Risk, High Reward

Sep 3, 2025, 7:00 AM EDT - 4 months ago

Fractyl Health Expands Board of Directors with Appointments of Industry Leaders to Advance Clinical Execution and Strategic Growth

Aug 12, 2025, 8:00 PM EDT - 4 months ago

Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 4 months ago

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Aug 7, 2025, 4:05 PM EDT - 4 months ago

Fractyl Health Announces Closing of $23 Million Underwritten Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

Aug 6, 2025, 8:30 AM EDT - 5 months ago

Fractyl Health Announces Pricing of $20 Million Underwritten Public Offering

Aug 5, 2025, 4:15 PM EDT - 5 months ago

Fractyl Health Announces Proposed Public Offering

Aug 5, 2025, 4:02 PM EDT - 5 months ago

Fractyl Health Reports Potent and Durable Two-Year Real-World Outcomes with Revita® Showing Sustained Weight Loss and Improved Glucose Control After a Single Procedure

Jul 16, 2025, 10:13 AM EDT - 5 months ago

Fractyl Health: Speculative Buy With Binary Risk

Jun 23, 2025, 7:40 AM EDT - 6 months ago

Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy

Jun 23, 2025, 7:30 AM EDT - 6 months ago

Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models

Jun 18, 2025, 7:00 AM EDT - 6 months ago

Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing

Jun 13, 2025, 7:00 AM EDT - 6 months ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions

Jun 4, 2025, 7:00 AM EDT - 7 months ago

Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide

May 19, 2025, 7:00 AM EDT - 7 months ago

Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes

May 17, 2025, 7:15 AM EDT - 7 months ago

Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025

May 14, 2025, 9:25 AM EDT - 8 months ago

Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases

May 13, 2025, 8:43 PM EDT - 8 months ago

Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 8 months ago

Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates

May 6, 2025, 7:00 AM EDT - 8 months ago

Fractyl Health to Report First Quarter 2025 Financial Results and Provide Business Updates on May 13, 2025, and Will Participate in an Upcoming Investor Conference

Apr 28, 2025, 4:30 PM EDT - 8 months ago

Fractyl Health to Present Compelling Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting

Apr 1, 2025, 7:00 AM EDT - 9 months ago

Fractyl Health Reports Positive Early Data Showing Revita® Has Potential to Prevent Weight Regain After GLP-1 Discontinuation

Mar 3, 2025, 8:01 PM EST - 10 months ago

Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:05 PM EST - 10 months ago

Fractyl Health Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Feb 24, 2025, 7:00 AM EST - 10 months ago

Fractyl Health to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 3, 2025

Jan 31, 2025, 8:01 AM EST - 11 months ago

Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025

Dec 12, 2024, 7:00 AM EST - 1 year ago

Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Dec 9, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)

Nov 26, 2024, 7:00 AM EST - 1 year ago

Fractyl Health to Participate in the Upcoming December Conferences

Nov 14, 2024, 11:01 PM EST - 1 year ago

Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 4:05 PM EST - 1 year ago

Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Present at Chardan's 8th Annual Genetic Medicines Conference

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Fractyl Health to Participate in Upcoming September Investor Conferences

Aug 14, 2024, 9:27 PM EDT - 1 year ago

Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript

LUVDAFOOD Dec. 23 at 4:26 PM

$GUTS Between 47 - 64 % discontinue GLP therapy ( nausea diarrhea) ReVita retains the gains made by GLP users - especially as to diabetes and weight profile

1 · Reply

willyield Dec. 23 at 3:15 PM

$GUTS

0 · Reply

Zkoko_Bio Dec. 23 at 1:13 AM

$GUTS $NVO Wegovy is a game changer hitting the market very soon. It also helps in keeping weight off, and that is Fractyl's territory...

0 · Reply

willyield Dec. 22 at 12:10 PM

$GUTS

0 · Reply

Ked1977 Dec. 19 at 4:19 PM

$GUTS does anyone think the Eli Lilly Orforglipron pill would be more of a competitor?

2 · Reply

SomsiHart Dec. 19 at 1:02 PM

Here are some small-cap stocks with potential to double: $ALT $MAAS $VOR $GUTS

1 · Reply

Quantumup Dec. 19 at 12:09 PM

0 · Reply

DSAdsdsas Dec. 19 at 5:00 AM

$GUTS

0 · Reply

ppl_first Dec. 18 at 10:05 PM

0 · Reply

ShadowBanningIsBad Dec. 18 at 9:46 PM

$GUTS ok I may have been too early to judge DMR. Does anyone know if $GUTS has IP that gives them a moat for DMR procedures?

0 · Reply

ShadowBanningIsBad Dec. 18 at 9:18 PM

$GUTS is overpriced slop, could be a great short play. My only hesitation is its some how approved in Germany. Will have to watch this one could be extremely volatile.

1 · Reply

Paultown1 Dec. 18 at 8:21 PM

$GUTS Love the huge volume on this today…building a base for next leg up IMO. January data is essentially Phase 2 data, but better than typical Phase 2 b/c it’s the EXACT protocol to the Phase 3 in Q3 next year—same patient criteria, same endpoints, exact same clinics, exact same doctors and almost exact/overlap in timing of execution…and exact same 6-month results (only difference is N = 45 in January and N = 315 in Q3). So yes, good data will move this stock SIGNIFICANTLY, just like most Phase 2 studies (and perhaps more since it’s the EXACT protocol)…many bios get 70% of their ultimate gains from Phase 2 results (vs Phase 3)…this one might be no different.

1 · Reply

BioRich Dec. 18 at 7:20 PM

$LLY Congrats on the great news for Orforglipron. Weight loss retension is truly the Holy Grail in the Obesity sector and this once daily pill is excellent news for the sector. The leader, in my opinion, for Weight Loss Retention to date is $GUTS (Fractyl Health). They have a 1 time procedure that has shown sustained weight loss following GLP-1 discontinuation. Because of this, it's my #1 Stock Pick, with a deal with $NVO or other BP not out of the question. Recent Results: https://ir.fractyl.com/news-releases/news-release-details/fractyl-health-reports-positive-6-month-reveal-1-open-label Click around on the website and I think you'll be very impressed. New (confirmatory) data expected in January. Again, congrats $LLY Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Lets make some money. Cheers! $XBI

1 · Reply

BioRich Dec. 18 at 7:08 PM

$GUTS Keep an eye on this one. Expect short term drift on $LLY news. Also expect $GUTS to use this news to blow the roof off of their treatment potential. This will go down as an epic day for $GUTS

1 · Reply

POPEYE832 Dec. 18 at 8:47 AM

$GUTS The insiders have just granted themselves stock options at a price of 2.24 with an expiration in 2035 — am I mistaken?

0 · Reply

BioRich Dec. 17 at 7:24 PM

$GUTS So after discovering this was a savage move to help $GUTS shareholders, I engaged the company to understand why they decided to do this now. Their response was simple: "The timing simply reflects that the contractual conditions to call the warrants were met. Details are described in that same 8K." Essentially, they hit the thresholds to call the warrants (which were already accounted for) and gave a very short period for warrant holders to execute. Every way I slice it, this is further confirmation of expected excellent data in Q1 (January, I believe). Exciting times. The "Race to 8" watch has officially begun for $GUTS and $MIST. I think we'll start with a "Race to 4" as a near-term target. https://www.sec.gov/Archives/edgar/data/1572616/000119312525319524/guts-ex99_2.htm Follow/subscribe for more suggestion and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some money. Cheers!

1 · Reply

Gaelic73 Dec. 17 at 6:17 PM

$GUTS Must be more warrant holders selling today.

0 · Reply

SuperGreenToday Dec. 17 at 6:00 PM

$GUTS

1 · Reply

DSAdsdsas Dec. 17 at 12:51 PM

$GUTS https://www.youtube.com/watch?v=1cL2hNIe2kg&t=2118s

0 · Reply

Stocktwits Dec. 17 at 12:38 AM

🚨 Chart of the Day by @ACInvestorBlog - $TSLA Breaks Out on Volume MACD and RSI Confirm Strength ⚡ Get the hottest trade ideas and daily insights in your inbox with the Chart Art newsletter! https://chartart.stocktwits.com/p/tuesday-d997 Also featured: @HostileCharts $IWM, @LiveTradePro $PLTR, @MichaelNaussCMT, @DavyDaveCharts $GUTS

1 · Reply

DavyDaveCharts Dec. 16 at 10:33 PM

$GUTS weekly: nice wick off of the bullish imbalance. 3.05-3.50?

0 · Reply

jerrybe5000 Dec. 16 at 7:41 PM

$GUTS I sold too soon. Strong resilience today in the face of the warrant redemption news. That's 17m that could potentially be offloaded onto the market.

1 · Reply

Market Cap	309.72M
Revenue (ttm)	90,000.00
Net Income (ttm)	-68.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-76,322.22%
Debt to Equity Ratio	-9.68

Volume	461,200
Avg Vol	2,913,622
Day's Range	N/A - N/A
Shares Out	137.04M
Stochastic %K	65%
Beta	1.96
Analysts	Strong Sell
Price Target	$7.44